Diabetes and osteoporosis: Action of gastrointestinal hormones on the bone
| Autor: | Rebeca Reyes-García, José Miguel García-Castro, Manuel Muñoz-Torres, Antonia García-Martín |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
business.industry Osteoporosis Type 2 Diabetes Mellitus General Medicine Type 2 diabetes medicine.disease Metformin chemistry.chemical_compound Endocrinology chemistry Diabetes mellitus Internal medicine medicine Microalbuminuria Glycated hemoglobin business Dyslipidemia medicine.drug |
| Zdroj: | Revista Clínica Española (English Edition). 213:293-297 |
| ISSN: | 2254-8874 |
| DOI: | 10.1016/j.rceng.2013.05.004 |
| Popis: | A 62-year-old woman consulted for evaluation of treatment for her type 2 diabetes diagnosed four years ago. He had been received treatment with metformin 850mg twice, with no chronic associated complications. She had hypertension and dyslipidemia. She was being treated with candesartan/hydrochlorothiazide 32/12.5mg and atorvastatin 40mg. Her weight was 92kg and height 162cm (BMI, 35.1kg/m(2)). The last analysis showed fasting glucose 168mg/dl and glycated hemoglobin 7.5%, Microalbuminuria was negative. Blood pressure and lipid profile were within the therapeutic range. Two years ago she suffered a nontraumatic Colle's fracture in her left arm for which she was taking a daily calcium and vitamin D supplement and weekly alendronate. In summary, this is an obese female patient with type 2 diabetes mellitus and inadequate metabolic control, She also has a history of fragility fracture. How should this patient be evaluated and treated? |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect